Mind Body Intervention for Chronic Upper Extremity Pain (Repetitive Stress Injury)
Beth Israel Deaconess Medical Center
40 participants
Mar 28, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this nonrandomized pilot study is to test a mind-body interventional approach for the treatment of chronic upper extremity pain or repetitive stress injury of the upper extremity (wrist/shoulder/elbow). 1. To determine if a mind-body intervention improves upper extremity functional capacity (ie., Disability of Arm Shoulder Hand - DASH) among people with chronic wrist, elbow, and shoulder pain 2. To determine if a mind-body intervention decreases pain intensity, pain-related anxiety, and overall somatic complaints in our trial participants. 3. To tailor the intervention and the outcomes assessment procedures for conducting a trial in a population with upper extremity pain.
Eligibility
Inclusion Criteria5
- Adult (≥ 18 years of age)
- A disability score ≥ 40 as per the QuickDASH survey
- Presence of pain and perceived disability for a minimum of 3 months
- Willing to engage in a Mind-Body intervention
- Positive visualization test (onset of pain when patients visualize themselves performing tasks that generally bring on pain)
Exclusion Criteria5
- Clear organic diagnosis of pain (e.g., cancer, infection, etc…) not inclusive of non-specific findings on imaging studies (e.g., mild arthritis)
- Age greater than 60 years (due to an increased risk of there being an organic/physical cause for their pain and confounding results)
- Diagnosis of cognitive impairment or dementia
- Active addiction disorder, e.g. cocaine or IV heroin use, that would interfere with study participation
- Major psychiatric comorbidity (e.g., schizophrenia). Anxiety and mild-moderate depression are not considered in this category
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The mind-body intervention will include regular approximate 2 hour educational sessions and didactics learning mind body techniques. The sessions will be twice per week for the first 4 weeks and then subsequently once per week for a total of 13 weeks.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06903962